Skip to content

Robot-assisted Gait Training in Multiple Sclerosis Subjects

The Effects of Robot-assisted Gait Training on Locomotor Function and Motor Unit Firing in Multiple Sclerosis Subjects With Severe Gait Impairments. A Randomized Control Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01435694
Enrollment
60
Registered
2011-09-19
Start date
2011-04-30
Completion date
2013-06-30
Last updated
2014-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

multiple sclerosis, gait rehabilitation

Brief summary

Aims of the study: This is a randomized-controlled trial to test the effects of robot-assisted gait training on locomotor function and motor unit firing rate in multiple sclerosis subjects with severe gait impairments. The control group will be treat with conventional physical therapy. Subjects and methods: 60 multiple sclerosis patients will be recruited in two outpatient rehabilitation clinics. Informed consent will be obtained. Participants will be randomized to Robot-assisted gait training (experimental group) or conventional therapy (control group) through a randomization stratification approach, according to a block randomization of 4. The experimental group will receive 12 robot-assisted gait training sessions over 6 weeks (2 sessions/week). The control group will receive 12 conventional therapy sessions over 6 weeks (2 sessions/week), that will focus on gait training. Primary outcome measures will be both neurophysiological measures (motor unit firing rate characteristics) and clinical test for gait speed (10m walking test). Secondary outcome measures will include: clinical tests of walking endurance (six minute walking test), balance (Berg Balance Test) and mobility (Up and Go Test). Clinical assessment of lower-extremities spasticity (Modified Ashworth Scale), motor fatigue (Fatigue Severity Scale), depression (PHQ-9) and quality of life (SF-36) will be monitored. Subject acceptance and confidence in the treatments will be track with a Visual Analog Scale. Outcome measures will be assessed the week prior to treatment initiation (T0), after 6 sessions (T1), the week after the end of treatment (T2) and at 3 months follow-up (T3) to evaluate treatments retention, by a clinician blinded to the treatment.

Interventions

BEHAVIORALLokomat (Hocoma, Switzerland)
BEHAVIORALConventional Therapy

Sponsors

Azienda Ospedaliero, Universitaria Pisana
CollaboratorOTHER
University Hospital of Ferrara
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* males and females, community dwelling, age 18 or older * diagnosis of multiple sclerosis in a stable phase, with relapses \> 6 months prior to study enrollment * moderate to severe gait impairments referred to Expanded Disability Status Scale (EDSS) between 6 and 7

Exclusion criteria

* neurologic conditions in addition to multiple sclerosis that may affect motor function * medical conditions likely to interfere with the ability to safely complete the study * impaired cognitive functioning: Mini Mental Status Examination \< 24 * severe lower-extremities spasticity or contractures that may limit range of motion(Ashworth score \>4 for hip, knee or ankle flexors/extensors

Design outcomes

Primary

MeasureTime frameDescription
motor unit firing rate characteristics12 monthsIt will be performed through the analysis of superficial EMG signals during isometric knee extension.

Secondary

MeasureTime frameDescription
mobility12 monthsTimed Up and Go Test
balance12 monthsBerg Balance Test
gait speed12 months10 meter test
walking endurance12 monthssix minute walking test
quality of life12 monthsSF-36
depression12 monthspatient health questionnaire (PHQ-9)
Fatigue12 monthsFatigue Severy Scale

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026